Wednesday, March 16, 2011 12:38:58 PM
PALO ALTO, Calif., Mar 16, 2011 (BUSINESS WIRE) -- Southwall Technologies Inc. /quotes/comstock/11k!swtx (SWTX 2.45, +0.05, +2.08%) , the worldwide innovator of energy-saving films and glass products that improve the energy efficiency of buildings, homes and cars, today announced that post reverse stock split trading will take effect at the open of business, March 17, 2011.
The new symbol on this date will be SWTXD. A "D" will be appended as the 5th character for 20 business days including the effective date.
About Southwall Technologies Inc.
Southwall Technologies is the leading innovator of energy-saving films and glass products that dramatically improve the energy efficiency of buildings, homes and cars. Southwall is an ISO 9001/14001 certified manufacturer with customers in over 25 countries around the world.
This press release may contain forward-looking statements, including, without limitation, statements regarding the Company's expectations, beliefs, intentions, or strategies regarding the future. All forward-looking statements in this press release are based on information available to the Company on the date hereof, and the Company assumes no obligation to update any such forward-looking statements. These statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those presented. These risks include the possibility that the Company's expected future results will be materially worse than estimated, that the Company may not continue to be profitable in future quarters or may not be able to achieve future long-term growth, that there will be a decline in one or more portions of our business in 2010 or thereafter, that the Company will not be successful in improving operations performance or controlling costs, that the Company will suffer a decline in manufacturing or financial effectiveness, that the Company's new product development will not be successful, that there may be decreasing demand in certain markets and that the Company will not be able to secure additional financing if required, as well as risks associated with its failure to meet potential covenant requirements under future credit facilities. Further risks are detailed in the Company's filings with the Securities and Exchange Commission, including those set forth in the Company's most recent Annual Report on Form 10-K for the year ended December 31, 2009, filed on March 25, 2010.
SOURCE: Southwall Technologies Inc.
Southwall Technologies Inc.
Kathy Taylor, 650-798-1200
Copyright Business Wire 2011
Comtex
Recent SWTX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 08:05:15 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/03/2024 08:09:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 08:05:26 PM
- FDA Grants Priority Review to SpringWorks Therapeutics’ New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN • GlobeNewswire Inc. • 08/28/2024 10:30:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 10:36:23 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2024 10:34:23 AM
- SpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights • GlobeNewswire Inc. • 08/07/2024 10:30:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 08:01:45 PM
- SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors • GlobeNewswire Inc. • 07/29/2024 10:30:11 AM
- SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024 • GlobeNewswire Inc. • 07/23/2024 11:00:02 AM
- Kuehn Law Encourages Investors of SpringWorks, Therapeutics Inc. to Contact Law Firm • PR Newswire (US) • 07/02/2024 04:49:00 PM
- SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN • GlobeNewswire Inc. • 07/01/2024 10:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 08:15:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 08:07:38 PM
- SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference • GlobeNewswire Inc. • 06/05/2024 11:00:52 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/03/2024 08:37:20 PM
- SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting • GlobeNewswire Inc. • 05/23/2024 09:13:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:53:56 PM
- SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference • GlobeNewswire Inc. • 05/08/2024 11:00:27 AM
- SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates • GlobeNewswire Inc. • 05/02/2024 10:30:00 AM
- SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting • GlobeNewswire Inc. • 04/24/2024 05:31:32 PM
- SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024 • GlobeNewswire Inc. • 04/18/2024 11:00:28 AM
- SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN • GlobeNewswire Inc. • 03/04/2024 11:30:11 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/01/2024 10:16:11 PM
- SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors • GlobeNewswire Inc. • 02/29/2024 01:30:13 PM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM
Unitronix Corp Unveils Cryptocurrency Investment Portfolio Strategy • UTRX • Oct 2, 2024 8:40 AM
Integrated Ventures, Inc Reports Total 2024 Revenues Of $5,863,935 vs $3,862,849 for 2023. • INTV • Oct 1, 2024 9:00 AM
Nightfood Signs Letter of Intent to Acquire Los Angeles Cooking School, Integrating Automation and Robotics with World-Class Culinary Training • NGTF • Oct 1, 2024 8:30 AM
ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • COOP • Oct 1, 2024 7:00 AM
Element79 Gold Corp secures loi for launching tailings reprocessing business in Arequipa, Peru • ELMGF • Oct 1, 2024 6:38 AM